文献速递中医内科中药与中成药合理使用

华佗再造丸治疗卒中随机对照试验的报告质量评价

The quality of reporting of randomized controlled trials of HuatuoZaizao pill for stroke.
PubMed 文献 · Front Pharmacol · 2023-01-10

该研究采用CONSORT及其草药干预扩展版(CONSORT-CHM)指南,评价华佗再造丸治疗卒中的随机对照试验报告质量。

要点

  • 华佗再造丸治疗卒中的RCT报告质量总体偏低,需按CONSORT-CHM规范报告。
  • 样本量计算、分配隐藏、盲法实施等关键方法学条目报告率仅6%。
  • 所有研究均未详细报告华佗再造丸的剂型、来源、处方依据等中药特征信息。

核心结论

  • 华佗再造丸相关RCT的总体报告质量较低,仍需开展更高质量的RCT以证明其有效性和安全性。

研究设计与样本

  • 采用CONSORT指南及CONSORT-CHM指南评价华佗再造丸治疗卒中的随机对照试验报告质量。
  • 使用Microsoft Excel 2007和SPSS20.0进行统计分析。

主要发现

  • CONSORT-CHM在CONSORT基础上扩展了24.3%(9/37)的条目并增加了一个小条目。
  • CONSORT评价平均得分为14.6,CONSORT-CHM评价平均得分为11.6。
  • CONSORT核心条目中,合格标准、样本量计算、主要结局、随机序列生成方法、分配隐藏、随机化实施、盲法描述和详细统计方法的报告率分别为77%、6%、100%、47%、6%、6%、6%和94%。
  • CONSORT-CHM方面,无文章详细报告华佗再造丸的剂型、来源、处方依据等,仅半数研究报告了与中医证候相关的结局指标。

关键数值与推荐

  • CONSORT核心条目报告率:合格标准77%、样本量计算6%、主要结局100%、随机序列生成方法47%、分配隐藏6%、随机化实施6%、盲法描述6%、详细统计方法94%。
  • CONSORT-CHM扩展了24.3%(9/37)的CONSORT条目并增加一个小条目。
  • CONSORT平均得分14.6,CONSORT-CHM平均得分11.6。

临床怎么用

  • 临床解读华佗再造丸治疗卒中的RCT证据时,需注意其方法学报告质量偏低,尤其应关注样本量计算、分配隐藏和盲法实施等关键环节的报告缺失。
  • 建议未来开展华佗再造丸RCT时,按照CONSORT-CHM指南完整报告中药制剂的剂型、来源、处方依据及中医证候结局指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: HuatuoZaizao pill (HZP), a Chinese patent medicine, is often used in the treatment of stroke. However, there is still a lack of enough evidence to recommend the routine use of HZP for stroke. This study is aimed at evaluating the quality of reporting of randomized controlled trials (RCTs) on HZP for stroke. Methods: RCTs on HuatuoZaizao pill for stroke were evaluated by using Consolidated Standards of Reporting Trials (CONSORT) guidelines and CONSORT extension criteria on reporting herbal interventions (CONSORT-CHM) guidelines. Microsoft Excel 2007 and SPSS20.0 was used for statistics analyses. Results: Seventeen studies involving 1801 stroke patients were identified. CONSORT-CHM has expanded 24.3% (9/37) items in CONSORT and added a small item. The average scores of CONSORT evaluation is 14.6, while the average scores of the CONSORT-CHM evaluation is 11.6. The central items in CONSORT as eligibility criterion, sample size calculation, primary outcome, method of randomization sequence generation, allocation concealment, implementation of randomization, description of blinding, and detailed statistical methods were reported in 77%, 6%, 100%, 47%, 6%, 6%, 6%, and 94% of trials, respectively. In terms of the CONSORT-CHM, none of the articles reported in detail the dosage form, origin, formula basis and so on of HZP, and only half of studies reported the outcome indicators related to Traditional Chinese Medicine syndromes. Conclusion: The overall report quality of RCT related to HZP is low. HZP still needs to report higher quality RCTs to prove its effectiveness and safety.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang XJ, Wang YJ, Lu X, et al. The quality of reporting of randomized controlled trials of HuatuoZaizao pill for stroke. Front Pharmacol. 2023. PMID: 36703753. doi:10.3389/fphar.2022.1106957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。